vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and ESCO TECHNOLOGIES INC (ESE). Click either name above to swap in a different company.
ESCO TECHNOLOGIES INC is the larger business by last-quarter revenue ($289.7M vs $247.1M, roughly 1.2× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 9.9%, a 1.2% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 17.3%). ESCO TECHNOLOGIES INC produced more free cash flow last quarter ($63.0M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 7.8%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Esco is a Singaporean brand that develops, manufactures, and sells products and services for laboratories.
ANIP vs ESE — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $289.7M |
| Net Profit | $27.5M | $28.7M |
| Gross Margin | — | 41.4% |
| Operating Margin | 14.1% | 13.2% |
| Net Margin | 11.1% | 9.9% |
| Revenue YoY | 29.6% | 17.3% |
| Net Profit YoY | 367.5% | 22.2% |
| EPS (diluted) | $1.14 | $1.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $289.7M | ||
| Q3 25 | $227.8M | $286.5M | ||
| Q2 25 | $211.4M | $296.3M | ||
| Q1 25 | $197.1M | $265.5M | ||
| Q4 24 | $190.6M | $247.0M | ||
| Q3 24 | $148.3M | $298.5M | ||
| Q2 24 | $138.0M | $260.8M | ||
| Q1 24 | $137.4M | $249.1M |
| Q4 25 | $27.5M | $28.7M | ||
| Q3 25 | $26.6M | $218.7M | ||
| Q2 25 | $8.5M | $26.1M | ||
| Q1 25 | $15.7M | $31.0M | ||
| Q4 24 | $-10.3M | $23.5M | ||
| Q3 24 | $-24.2M | $34.3M | ||
| Q2 24 | $-2.3M | $29.2M | ||
| Q1 24 | $18.2M | $23.2M |
| Q4 25 | — | 41.4% | ||
| Q3 25 | — | 45.9% | ||
| Q2 25 | — | 41.2% | ||
| Q1 25 | — | 41.1% | ||
| Q4 24 | — | 39.8% | ||
| Q3 24 | — | 40.1% | ||
| Q2 24 | — | 39.6% | ||
| Q1 24 | — | 38.8% |
| Q4 25 | 14.1% | 13.2% | ||
| Q3 25 | 15.9% | 17.2% | ||
| Q2 25 | 6.6% | 11.2% | ||
| Q1 25 | 13.3% | 15.3% | ||
| Q4 24 | -2.3% | 11.4% | ||
| Q3 24 | -13.8% | 14.8% | ||
| Q2 24 | 3.7% | 14.3% | ||
| Q1 24 | 14.8% | 11.7% |
| Q4 25 | 11.1% | 9.9% | ||
| Q3 25 | 11.7% | 76.3% | ||
| Q2 25 | 4.0% | 8.8% | ||
| Q1 25 | 8.0% | 11.7% | ||
| Q4 24 | -5.4% | 9.5% | ||
| Q3 24 | -16.3% | 11.5% | ||
| Q2 24 | -1.7% | 11.2% | ||
| Q1 24 | 13.2% | 9.3% |
| Q4 25 | $1.14 | $1.11 | ||
| Q3 25 | $1.13 | $8.43 | ||
| Q2 25 | $0.36 | $1.01 | ||
| Q1 25 | $0.69 | $1.20 | ||
| Q4 24 | $-0.45 | $0.91 | ||
| Q3 24 | $-1.27 | $1.32 | ||
| Q2 24 | $-0.14 | $1.13 | ||
| Q1 24 | $0.82 | $0.90 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $103.8M |
| Total DebtLower is stronger | — | $145.5M |
| Stockholders' EquityBook value | $540.7M | $1.6B |
| Total Assets | $1.4B | $2.4B |
| Debt / EquityLower = less leverage | — | 0.09× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $103.8M | ||
| Q3 25 | $262.6M | $101.3M | ||
| Q2 25 | $217.8M | $78.7M | ||
| Q1 25 | $149.8M | $57.4M | ||
| Q4 24 | $144.9M | $71.3M | ||
| Q3 24 | $145.0M | $66.0M | ||
| Q2 24 | $240.1M | $63.0M | ||
| Q1 24 | $228.6M | $59.4M |
| Q4 25 | — | $145.5M | ||
| Q3 25 | — | $186.0M | ||
| Q2 25 | — | $525.0M | ||
| Q1 25 | — | $88.0M | ||
| Q4 24 | — | $112.0M | ||
| Q3 24 | — | $122.0M | ||
| Q2 24 | — | $173.0M | ||
| Q1 24 | — | $191.0M |
| Q4 25 | $540.7M | $1.6B | ||
| Q3 25 | $505.8M | $1.5B | ||
| Q2 25 | $436.8M | $1.3B | ||
| Q1 25 | $418.6M | $1.3B | ||
| Q4 24 | $403.7M | $1.2B | ||
| Q3 24 | $405.9M | $1.2B | ||
| Q2 24 | $455.8M | $1.2B | ||
| Q1 24 | $452.0M | $1.2B |
| Q4 25 | $1.4B | $2.4B | ||
| Q3 25 | $1.4B | $2.4B | ||
| Q2 25 | $1.3B | $2.5B | ||
| Q1 25 | $1.3B | $1.8B | ||
| Q4 24 | $1.3B | $1.8B | ||
| Q3 24 | $1.3B | $1.8B | ||
| Q2 24 | $920.8M | $1.8B | ||
| Q1 24 | $914.5M | $1.8B |
| Q4 25 | — | 0.09× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.07× | ||
| Q4 24 | — | 0.09× | ||
| Q3 24 | — | 0.10× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.16× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $68.9M |
| Free Cash FlowOCF − Capex | $29.1M | $63.0M |
| FCF MarginFCF / Revenue | 11.8% | 21.7% |
| Capex IntensityCapex / Revenue | 0.5% | 2.0% |
| Cash ConversionOCF / Net Profit | 1.10× | 2.40× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $239.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $68.9M | ||
| Q3 25 | $44.1M | $109.9M | ||
| Q2 25 | $75.8M | $73.7M | ||
| Q1 25 | $35.0M | $24.1M | ||
| Q4 24 | $15.9M | $34.2M | ||
| Q3 24 | $12.5M | $72.1M | ||
| Q2 24 | $17.4M | $36.2M | ||
| Q1 24 | $18.3M | $10.5M |
| Q4 25 | $29.1M | $63.0M | ||
| Q3 25 | $38.0M | $97.8M | ||
| Q2 25 | $71.8M | $64.9M | ||
| Q1 25 | $32.5M | $14.0M | ||
| Q4 24 | $13.5M | $29.0M | ||
| Q3 24 | $7.7M | $60.9M | ||
| Q2 24 | $13.0M | $27.6M | ||
| Q1 24 | $13.7M | $2.0M |
| Q4 25 | 11.8% | 21.7% | ||
| Q3 25 | 16.7% | 34.1% | ||
| Q2 25 | 34.0% | 21.9% | ||
| Q1 25 | 16.5% | 5.3% | ||
| Q4 24 | 7.1% | 11.7% | ||
| Q3 24 | 5.2% | 20.4% | ||
| Q2 24 | 9.4% | 10.6% | ||
| Q1 24 | 10.0% | 0.8% |
| Q4 25 | 0.5% | 2.0% | ||
| Q3 25 | 2.7% | 4.2% | ||
| Q2 25 | 1.9% | 3.0% | ||
| Q1 25 | 1.3% | 3.8% | ||
| Q4 24 | 1.3% | 2.1% | ||
| Q3 24 | 3.2% | 3.8% | ||
| Q2 24 | 3.2% | 3.3% | ||
| Q1 24 | 3.3% | 3.4% |
| Q4 25 | 1.10× | 2.40× | ||
| Q3 25 | 1.66× | 0.50× | ||
| Q2 25 | 8.87× | 2.83× | ||
| Q1 25 | 2.23× | 0.78× | ||
| Q4 24 | — | 1.46× | ||
| Q3 24 | — | 2.10× | ||
| Q2 24 | — | 1.24× | ||
| Q1 24 | 1.00× | 0.45× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
ESE
| US Government | $98.0M | 34% |
| Utility Solutions Group | $87.5M | 30% |
| RF Shielding And Test | $58.3M | 20% |
| Commercial | $45.8M | 16% |
| Related Party | $1.3M | 0% |
